The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Role of basal inflammatory status as a predictor of survival in bevacizumab-treated advanced non-small cell lung cancer (NSCLC) patients.
C. Botta
No relevant relationships to disclose
A. Guglielmo
No relevant relationships to disclose
E. Bestoso
No relevant relationships to disclose
S. Apollinari
No relevant relationships to disclose
A. Licchetta
No relevant relationships to disclose
P. Blardi
No relevant relationships to disclose
P. Tassone
No relevant relationships to disclose
G. Chiriaco
No relevant relationships to disclose
V. Barbieri
No relevant relationships to disclose
G. Mantovani
No relevant relationships to disclose
P. Tagliaferri
No relevant relationships to disclose
P. Correale
No relevant relationships to disclose